Navigation Links
CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
Date:2/15/2012

PRINCETON, New Jersey, February 15, 2012 /PRNewswire/ --

CitiusTech, a leading healthcare technology solution provider, announced that it has completed the calendar year 2011 with 59% growth in revenues. 2011 is now the fifth consecutive year that CitiusTech has recorded over 50% Y-o-Y revenue growth. In 2011, CitiusTech won the Red Herring Award for leadership in healthcare technology. CitiusTech was selected as a finalist at the 2011 American Business Awards for being one of the fastest growing technology companies in the United States.

Growth in 2011 has been driven by existing customer relationships (93% customer retention) and by new customer additions across North America and Europe.  CitiusTech also enhanced its capabilities across its key service offerings - software product engineering, professional services and healthcare BI/analytics. CitiusTech's BI-Clinical platform became the only modular BI solution to be ONC-ATCB 2011/2012 certified for all Eligible Hospital (EH) and Eligible Professional (EP) Meaningful Use Clinical Quality Measures. BI-Clinical was also one of the first BI/analytics platforms to comply with all 33 ACO quality measures that were released by CMS.

During 2011, CitiusTech's software engineering practice enabled many leading healthcare IT vendors to enhance and architect their solutions (e.g., for mobile and cloud computing) and comply with new technology and regulatory needs (including Meaningful Use, ACO etc.). In addition, CitiusTech professional services team formed strategic partnerships with HIE, EMR and clinical application organizations to help them scale their professional services organizations worldwide. With over 250 HL7 certified professionals, CitiusTech retains the distinction of having the largest number of certified interoperability professionals worldwide. CitiusTech also expanded its reach, with new offices in Princeton NJ, Singapore and India.

"2011 has been an excellent year for CitiusTech. Our ability to form and grow long-term partnerships with healthcare technology organizations and support their business growth has been key to our success," said Rizwan Koita, CEO, CitiusTech. "Our BI-Clinical platform has been strongly received by our partners for population health management, care coordination and quality reporting."

About CitiusTech

CitiusTech is a specialist provider of healthcare technology services and solutions to healthcare IT vendors, providers, ACOs,and health plans. CitiusTech offers a wide range of healthcare technology services including healthcare software development, healthcare interoperability, Meaningful Use compliance, BI /analytics, care management and consumer health.

CitiusTech's BI-Clinical platform is s market leader in healthcare BI/ analytics. CitiusTech brings strong healthcare expertise across technologies, applications and standards. Our ability to providethis expertise, together with world-class service quality and aglobal resource base, enables us to deliver best-in- class solutions and an unmatched cost advantage to healthcare clients worldwide.


For further information:
CitiusTech Inc.
Sujay Pal
Manager - Corporate Marketing
sujay.pal@citiustech.com
+1-877-248-4871



'/>"/>
SOURCE CitiusTech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
4. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Roche completes acquisition of ARIUS
10. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
11. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
(Date:2/16/2017)... and NEW YORK , Feb. 16, ... completion of their $7M Series B financing, adding an ... the $3.5M led by Mesa Verde Venture Partners and ... resources will be directed towards further accelerating commercial adoption ... comprehensive genomic profiling test and expanding the Paradigm cancer ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to its ... meaningful advances worldwide, The Japan Prize Foundation today ... who have pushed the envelope in their respective ... Communication. Three scientists are being recognized with the ... that not only contribute to the advancement of ...
(Date:1/31/2017)... Jan. 31, 2017  Spero Therapeutics, LLC, a ... the treatment of bacterial infections, today announced it ... candidates from Pro Bono Bio Ltd (PBB) to ... multi-drug resistant forms of Gram-negative bacteria.   The assets ... Ltd, a PBB group company. "The ...
Breaking Biology News(10 mins):